408 related articles for article (PubMed ID: 16762007)
1. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
[TBL] [Abstract][Full Text] [Related]
3. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
4. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
5. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
6. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.
Yeon JE; Choi KM; Baik SH; Kim KO; Lim HJ; Park KH; Kim JY; Park JJ; Kim JS; Bak YT; Byun KS; Lee CH
J Gastroenterol Hepatol; 2004 Jul; 19(7):799-804. PubMed ID: 15209628
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
Aasum E; Khalid AM; Gudbrandsen OA; How OJ; Berge RK; Larsen TS
J Mol Cell Cardiol; 2008 Jan; 44(1):201-9. PubMed ID: 17931655
[TBL] [Abstract][Full Text] [Related]
10. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.
Tanaka T; Masuzaki H; Ebihara K; Ogawa Y; Yasue S; Yukioka H; Chusho H; Miyanaga F; Miyazawa T; Fujimoto M; Kusakabe T; Kobayashi N; Hayashi T; Hosoda K; Nakao K
Metabolism; 2005 Nov; 54(11):1490-8. PubMed ID: 16253638
[TBL] [Abstract][Full Text] [Related]
11. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
Ferreira AV; Parreira GG; Porto LC; Mario EG; Delpuerto HL; Martins AS; Botion LM
Life Sci; 2008 Apr; 82(15-16):876-83. PubMed ID: 18374364
[TBL] [Abstract][Full Text] [Related]
13. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation.
Nanji AA; Dannenberg AJ; Jokelainen K; Bass NM
J Pharmacol Exp Ther; 2004 Jul; 310(1):417-24. PubMed ID: 15016835
[TBL] [Abstract][Full Text] [Related]
14. Effects of the peroxisome proliferator-activated receptor-alpha agonists clofibrate and fish oil on hepatic fatty acid metabolism in weaned dairy calves.
Litherland NB; Bionaz M; Wallace RL; Loor JJ; Drackley JK
J Dairy Sci; 2010 Jun; 93(6):2404-18. PubMed ID: 20494149
[TBL] [Abstract][Full Text] [Related]
15. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.
Yamazaki K; Kuromitsu J; Tanaka I
Biochem Biophys Res Commun; 2002 Jan; 290(3):1114-22. PubMed ID: 11798191
[TBL] [Abstract][Full Text] [Related]
16. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
17. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice.
Skrtic S; Carlsson L; Ljungberg A; Lindén D; Michalik L; Wahli W; Oscarsson J
Liver Int; 2005 Feb; 25(1):33-40. PubMed ID: 15698396
[TBL] [Abstract][Full Text] [Related]
19. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice.
Park HJ; DiNatale DA; Chung MY; Park YK; Lee JY; Koo SI; O'Connor M; Manautou JE; Bruno RS
J Nutr Biochem; 2011 Apr; 22(4):393-400. PubMed ID: 20655714
[TBL] [Abstract][Full Text] [Related]
20. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
